Retinopathy of Prematurity Market Projected to Grow 3% Annually to 2036
The Retinopathy of Prematurity (ROP) market is projected to grow at a compound annual growth rate of approximately 3% to reach $20 million by 2036, driven by increased adoption of anti-VEGF therapies and emerging treatments.
The market for Retinopathy of Prematurity (ROP) is anticipated to grow steadily, reaching an estimated $20 million by 2036 from approximately $14 million in 2025. This growth is attributed to rising incidence rates, increased screening and diagnosis, and the expanding use of anti-VEGF therapies.
Across seven major markets (7MM), including the US, EU4 countries, the UK, and Japan, approximately 94,500 incident cases of ROP in preterm infants weighing 1,500g or less were recorded in 2025. The United States accounted for about 18,200 of these cases in the same year.
Key pharmacological treatments, such as aflibercept (Eylea) and ranibizumab (Lucentis), are currently approved and utilized. Laser photocoagulation remains a standard treatment for severe ROP, representing the largest revenue share among treatment approaches in 2025. Additionally, novel therapies like FLQ-101 and IBP-1118 are under development.
Major companies active in the ROP treatment landscape include Regeneron Pharmaceuticals, Novartis, and Bayer. The ongoing development of new therapies and the continued reliance on established treatments are expected to shape the market dynamics through 2036.